$928 Million is the total value of Rhenman & Partners Asset Management AB's 85 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 10.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Sell | UNITED HEALTH GROUP INC | $23,192,740 | -19.6% | 46,000 | -23.3% | 2.50% | -17.7% |
| CI | Sell | CIGNA CORP NEW | $22,885,600 | -29.1% | 80,000 | -30.4% | 2.47% | -27.5% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $18,591,985 | +3.4% | 143,634 | -0.9% | 2.00% | +5.8% |
| ANTM | Sell | ELEVANCE HEALTH INC | $16,545,960 | -33.5% | 38,000 | -32.1% | 1.78% | -32.0% |
| BIIB | Sell | BIOGEN INC | $14,521,065 | -21.0% | 56,500 | -12.4% | 1.57% | -19.2% |
| IMGN | Sell | IMMUNOGEN INC | $11,109,000 | -21.5% | 700,000 | -6.7% | 1.20% | -19.7% |
| EXAS | Sell | EXACT SCIENCES CORP | $10,915,200 | -33.6% | 160,000 | -8.6% | 1.18% | -32.0% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $6,733,200 | -66.5% | 60,000 | -56.5% | 0.73% | -65.7% |
| BNTX | Sell | BIONTECH SEsponsored ads | $5,757,920 | -23.8% | 53,000 | -24.3% | 0.62% | -22.0% |
| GKOS | Sell | GLAUKOS CORP | $5,493,250 | -18.8% | 73,000 | -23.2% | 0.59% | -17.0% |
| VEEV | Sell | VEEVA SYS INC | $4,679,350 | -32.4% | 23,000 | -34.3% | 0.50% | -30.7% |
| MRNA | Sell | MODERNA INC | $3,098,700 | -43.3% | 30,000 | -33.3% | 0.33% | -42.0% |
| TECH | Sell | BIO-TECHNE CORP | $2,905,228 | -25.1% | 42,680 | -10.1% | 0.31% | -23.5% |
| TXG | Sell | 10X GENOMICS INC | $2,805,000 | -63.1% | 68,000 | -50.0% | 0.30% | -62.3% |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $2,669,903 | -63.9% | 81,474 | -61.2% | 0.29% | -63.0% |
| INSP | Sell | INSPIRE MED SYS INC | $1,389,080 | -72.2% | 7,000 | -54.5% | 0.15% | -71.5% |
| OM | Sell | OUTSET MED INC | $544,000 | -92.5% | 50,000 | -84.9% | 0.06% | -92.3% |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -253,832 | -100.0% | -0.04% | – |
| MOH | Exit | MOLINA HEALTHCARE INC | $0 | – | -21,700 | -100.0% | -0.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.